Amylyx Targets Inflammation and Oxidative Stress with ALS Drug Combo

Cambridge, MA-based Amylyx Pharmaceuticals has received $600k in funding from the ALS Finding a Cure Foundation and the Cure Alzheimer’s Fund to advance preclinical development of its lead candidate, AMX0035. The drug is a proprietary combination of two compounds, which have shown potent anti-inflammatory and neuroprotective effects in preclinical studies in ALS, Alzheimer’s and other neurodegenerative diseases. The compounds act by synergistically blocking mitochondrial and ER stress. Amylyx plans to enter clinical trials in ALS in 2016 and with the help of the recent grants will fund IND-enabling studies to advance toward this goal.

Click here to read more.

disease-als topic-preclinical topic-randd
Share this: